Swiss biotech CSO/CMO meeting
Wednesday, September 2, 2026, 9:30 - 17:30 and evening reception
Fondation ISREC, Bâtiment AGORA, Rue du Bugnon 25A, 1005 Lausanne
We are delighted to invite you to our first informal peer-to-peer meeting for chief scientific and chief medical officers.
Join us for a program designed to guide you through the critical stages of drug development. Experienced scientific and medical leaders share practical insights, real-world lessons, and actionable strategies across both non-clinical and clinical development phases in an informal setting.
Through expert talks and interactive discussions, the meeting fosters collaboration and strengthens excellence across the Swiss biotech ecosystem.
Help shape a relevant and impactful program—share your input during registration.
Know a CSO/CMO who should join?
Please share the contact details of any CSO/CMO peers (full name, organization, email, function) whom you believe we should also invite. Alternatively, you may forward the invitation to them directly. If your organization does not have a dedicated CSO/CMO, you are kindly invited to register yourself.
Join us at the SITC EU Immuno-Oncology Drug Development Summit
After the CSO/CMO meeting, continue at the SITC EU Immuno-Oncology Drug Development Summit at the same venue on September 3, 2026. All CSO/CMO meeting participants, as well as Swiss Biotech Association members benefit from a 10% discount.
Preliminary program
More program details and speakers will be announced in due course…
9:30
Welcome coffee
9:45 – 10:45
From leads to development: Key insights and strategies to move from research to non-clinical development for small molecules and biologics
Madiha Derouazi, CEO, SwitchKine
Michael Altorfer, CEO, Swiss Biotech Association
10:45 – 11:15
Experiences from a drug hunter
11:15 – 12:15
CSO roundtable on key learnings and common pitfalls
Marc Ceusters, Head of Development, Switchkine
Martine Clozel, CSO, Idorsia
Davide Corti, SVP Antibody Research, Vir Biotechnology
Jonathan Kearsey, Co-founder & Managing Director, Leads To Development
Frédéric Levy, CSO, Head of external & internal innovation, Debiopharm
Martin Steegmaier, CSO, Molecular Partners